Molesense Raised CHF 150,000 from VentureKick
Share this article
EPFL spin-off MoleSense aims at bringing molecular wearables to maternity care. These devices will continuously and non-invasively monitor key biochemical markers in high-risk pregnancies, enabling doctors to make data-driven decisions and mothers to receive proactive care.
Preterm birth and pregnancy complications remain among the most pressing challenges in maternal health. When a mother’s water breaks too early, doctors face a difficult dilemma: delay delivery and risk infection or induce birth and risk lifelong complications for the baby. With no reliable way to quantify these risks, mothers often undergo invasive tests while clinicians must make life-or-death decisions with limited data.
The EPFL spin-off MoleSense is redefining women’s healthcare with a new class of wearables that track inflammatory proteins and steroid hormones in real time through non-invasive sweat monitoring using a “wear & forget” device. By combining personalized molecular data with biology-aware machine intelligence, the technology provides real-time, actionable insights for early diagnosis and targeted interventions.
Founded and led by Gian Luca Barbruni and Ata Golparvar, both PhD graduates from EPFL, MoleSense brings together deep expertise in micro- and nano-engineering and wearable technologies. The team is initially focusing on pregnancy management, aiming to impact more than eight million pregnancies annually across Switzerland, Europe, and the United States. Their approach sets a new standard for proactive, personalized maternity care and targets the USD 110 billion women’s healthcare device market, beginning its rollout with high-risk pregnancy centers such as CHUV.
The CHF 150,000 from Venture Kick will help the Medtech startup complete validation and move forward along the regulatory pathway toward early market entry.
“Venture Kick challenged us to think bigger, move faster, and sharpen our vision,” commented CEO Gian Luca Barbruni.
➡️ Source: Venture Kick Press Release | 📸 ©Molesense/Venture Kick. Gian Luca Barbruni, CEO, MoleSense.